by Madaline Spencer | Jan 21, 2025
Marina Kremyanskaya, MD, PhD, Icahn School of Medicine at Mount Sinai, discusses the development of gene silencer divesiran for treatment of polycythemia vera (PV). PV is a myeloproliferative disorder characterized by an elevated absolute red blood cell...
by CheckRare Staff | Mar 3, 2022
Stefan M. Schieke, MD, Assistant Professor of Dermatology at University of Wisconsin-Madison, discusses how cutaneous T-cell lymphomas (CTCL) are typically treated. There are many, multimodal treatment options for the various CTCL subtypes. In addition to...
by CheckRare Staff | Dec 22, 2021
Brendan Delaney, MBA, Chief Operating Officer of Aadi Bioscience, provides an overview of malignant perivascular epithelioid cell tumor (PEComa) and its treatment. As Mr. Delaney explains, PEComa is an ultra-rare family of sarcomas. Most PEComa begin as benign...
by Peter Ciszewski | Oct 2, 2021
The U.S. Food and Drug Administration (FDA) has approved brexucabtagene autoleucel (Tecartus) for the treatment of adult patients (18 years and older) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). This is the second indication for...
by Peter Ciszewski | Sep 28, 2021
Thierry Facon, MD, Professor of Hematology at Lille University Hospital in France, discusses 5-year follow-up data from the MAIA study evaluated the addition of daratumumab to the standard of care with lenalidomide and dexamethasone in multiple myeloma...
